SCYNEXIS, Inc. Increase (Decrease) in Accrued Liabilities
SCYNEXIS, Inc. (SCYX) reported Increase (Decrease) in Accrued Liabilities of -$757.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-10
- SCYNEXIS, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $655.00K.
- SCYNEXIS, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$1.41M.
- SCYNEXIS, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $17.00K.
- SCYNEXIS, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $297.00K, a 2870.00% increase year-over-year.
- SCYNEXIS, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was -$1.00M.
- SCYNEXIS, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was -$3.70M, a 298.34% decline from fiscal 2023.
- SCYNEXIS, Inc. increase (decrease) in accrued liabilities for fiscal 2023 was $1.87M.
- SCYNEXIS, Inc. increase (decrease) in accrued liabilities for fiscal 2022 was -$70.00K.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $655.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$757.00K 10-Q · filed 2026-08-10 | -$740.00K derived: sum of 3 quarters · filed 2026-08-10 | -$443.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$1.41M 10-Q · filed 2026-05-11 | -$1.40M derived: sum of 2 quarters · filed 2026-05-11 | -$1.10M derived: sum of 3 quarters · filed 2026-05-11 | -$1.25M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $314.00K derived: sum of 2 quarters · filed 2026-03-04 | $161.00K derived: sum of 3 quarters · filed 2026-08-10 | -$1.00M 10-K · filed 2026-03-04 |
| 2025-09-30 | $297.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $144.00K derived: sum of 2 quarters · filed 2026-08-10 | -$1.02M 10-Q · filed 2025-11-05 | -$2.73M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$153.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$1.32M 10-Q · filed 2026-08-10 | -$3.03M derived: sum of 3 quarters · filed 2026-08-10 | -$3.02M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$1.16M 10-Q · filed 2026-05-11 | -$2.88M derived: sum of 2 quarters · filed 2026-05-11 | -$2.87M derived: sum of 3 quarters · filed 2026-05-11 | -$1.97M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$1.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$1.70M derived: sum of 2 quarters · filed 2026-03-04 | -$808.00K derived: sum of 3 quarters · filed 2026-03-04 | -$3.70M 10-K · filed 2026-03-04 |
| 2024-09-30 | $10.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $906.00K derived: sum of 2 quarters · filed 2025-11-05 | -$1.99M 10-Q · filed 2025-11-05 | -$4.04M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $896.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$2.00M 10-Q · filed 2025-08-13 | -$4.05M derived: sum of 3 quarters · filed 2025-08-13 | -$1.69M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$2.89M 10-Q · filed 2025-05-15 | -$4.94M derived: sum of 2 quarters · filed 2025-05-15 | -$2.59M derived: sum of 3 quarters · filed 2025-05-15 | -$174.00K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$2.05M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $304.00K derived: sum of 2 quarters · filed 2025-03-12 | $2.72M derived: sum of 3 quarters · filed 2025-03-12 | $1.87M 10-K · filed 2025-03-12 |
| 2023-09-30 | $2.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $4.77M derived: sum of 2 quarters · filed 2024-11-06 | $3.92M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $2.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.56M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | -$853.00K 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | -$70.00K 10-K · filed 2024-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |